

# IDEXX LABORATORIES INC.

ISIN: US45168D1046 WKN: 45168D104 Asset Class: Stock

## Company

2024/08/20 22:00:00



Price

**494.01**

USD

Difference

-0.60%(-2.98)



## Contact Details

IDEXX LABORATORIES INC. Tel: +1-207-556-0300  
 -- Fax: +1-207-556-4346  
 One IDEXX Drive Web: <http://www.idexx.com>  
 04092-2040 Westbrook E-mail: -

## Company Profile

IDEXX Laboratories, Inc. engages in the development, manufacture, and distribution of products and services for the animal veterinary, livestock and poultry, dairy, and water testing markets. It operates through the following segments: Companion Animal Group (CAG), Water Quality Products (Water), Livestock, Poultry, and Dairy (LPD), and Other. The CAG segment provides diagnostic and information management-based products and services for the companion animal veterinary industry, including in-clinic diagnostic solutions, outside reference laboratory services, and veterinary software and services. The Water segment offers innovative testing solutions for easy, rapid, and accurate detection and quantification of various microbiological parameters in water. The LPD segment develops diagnostic tests, services, and related instrumentation that are used to manage the health status of livestock and poultry, to improve producer efficiency, and to ensure the quality and safety of milk and food. The Other segment is composed of products for the human point-of-care medical diagnostics market with its out-licensing arrangements. The company was founded by David Evans Shaw on December 19, 1983, and is headquartered in Westbrook, ME.

## Financial figures, Fiscal year: from 01.01. to 31.12.

| Financial figures                     | 2023          |                        | 2022          |                        | 2021          |                        |
|---------------------------------------|---------------|------------------------|---------------|------------------------|---------------|------------------------|
|                                       | Assets        | Liabilities and equity | Assets        | Liabilities and equity | Assets        | Liabilities and equity |
| <b>Current assets</b>                 | 1,441,173,000 |                        | 1,044,229,000 |                        | 900,238,000   |                        |
| <b>Common stock capital</b>           |               | 10,751,000             |               | 10,719,000             |               | 10,688,000             |
| <b>Fixed assets</b>                   | 1,818,752,000 |                        | 1,702,536,000 |                        | 1,536,965,000 |                        |
| <b>Equity capital of a company</b>    |               | 1,484,530,000          |               | 608,737,000            |               | 689,992,000            |
| <b>Cash and cash equivalents</b>      | 453,932,000   |                        | 112,546,000   |                        | 144,454,000   |                        |
| <b>Accrued liabilities</b>            |               | 0                      |               | 0                      |               | 0                      |
| <b>Other assets</b>                   | -             |                        | -             |                        | -             |                        |
| <b>Current liabilities</b>            |               | 951,547,000            |               | 1,235,803,000          |               | 763,579,000            |
| <b>Prepayments and accrued income</b> | -             |                        | -             |                        | -             |                        |
| <b>Non-current liabilities</b>        |               | 823,848,000            |               | 902,225,000            |               | 983,632,000            |
| <b>Different income</b>               |               | -                      |               | -                      |               | -                      |
| <b>Other liabilities</b>              |               | 94,059,000             |               | 98,449,000             |               | 112,115,000            |
| <b>Total assets</b>                   | 3,259,925,000 | 3,259,925,000          | 2,746,765,000 | 2,746,765,000          | 2,437,203,000 | 2,437,203,000          |

## Balance notes

|                            | 2023    | 2022    | 2021    |
|----------------------------|---------|---------|---------|
| <b>Accounting standard</b> | US-GAAP | US-GAAP | US-GAAP |
| <b>Employees</b>           | 11,000  | 10,780  | 10,350  |
| <b>Equity ratio</b>        | 45.54%  | 22.16%  | 28.31%  |
| <b>Debt-equity ratio</b>   | 119.59% | 351.22% | 253.22% |

## Others

|                         | 2023   | 2022   | 2021   |
|-------------------------|--------|--------|--------|
| <b>Tax Expense Rate</b> | 20.37% | 21.03% | 17.48% |

# IDEXX LABORATORIES INC.

ISIN: US45168D1046

WKN: 45168D104

Asset Class: Stock

## Income statement

|   | 2023          | 2022          | 2021          |
|---|---------------|---------------|---------------|
| Turnover  | 3,660,953,000 | 3,367,324,000 | 3,215,360,000 |
| Net income  | 845,042,000   | 679,089,000   | 744,845,000   |
| EBIT  | 999,922,459   | 821,686,341   | 852,002,239   |
| Operating income before taxes                                 | 1,061,176,000 | 859,972,000   | 902,654,000   |
| Cash Flow   | 906,510,000   | 542,549,000   | 752,896,000   |
| Net interest income   | -35,952,000   | -41,593,000   | -32,174,000   |
| Research and development expenses                             | 190,951,000   | 254,820,000   | 161,009,000   |
| Income taxes  | 216,134,000   | 180,883,000   | 157,810,000   |
| Result from investments in subsidiaries, associates and other | 0             | 0             | 0             |
| Revenues per employee   | 303,327       | 284,692       | 283,138       |

## Board of Directors

## Members of Management Board

|                     |                                |
|---------------------|--------------------------------|
| Lawrence Kingsley   | Chairman of Board of Directors |
| Asha Collins        | Member of Board of Directors   |
| Sophie Vandebroek   | Member of Board of Directors   |
| Stuart Essig        | Member of Board of Directors   |
| Bruce Clafin        | Member of Board of Directors   |
| Daniel Junius       | Member of Board of Directors   |
| Irene Britt         | Member of Board of Directors   |
| Jonathan Ayers      | Member of Board of Directors   |
| M. Szostak          | Member of Board of Directors   |
| Sam Samad           | Member of Board of Directors   |
| Jay Mazelsky        | Chairman of Managing Board     |
| Brian P. McKeon     | Member of Executive Committee  |
| James F. Polewaczyk | Member of Executive Committee  |
| Ken Grady           | Member of Executive Committee  |
| Martin Smith        | Member of Executive Committee  |
| Michael P. Johnson  | Member of Executive Committee  |